Lymphoma Clinical Trials in Florida

Showing 121-140 of 155 trials

Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms

NCT00082784

Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as flavopiridol, work in different ways to stop cancer cells from dividing so they stop growing or die. Bortezomib may increase the effectiveness of flavopiridol by making cancer cells more sensitive to the drug. Giving bortezomib together with flavopiridol may kill more cancer cells. This phase I trial is studying the side effects and best dose of bortezomib and flavopiridol in treating patients with recurrent or refractory indolent B-cell neoplasms.

Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueNodal Marginal Zone LymphomaRecurrent Adult Diffuse Large Cell Lymphoma+10 more

National Cancer Institute (NCI)93 participantsStarted Mar 2004

Tampa, Florida, United States • Pittsburgh, Pennsylvania, United States • Pittsburgh, Pennsylvania, United States +2 more locations

COMPLETEDPHASE349 miles

Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease

NCT00005578

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as dexrazoxane, may protect normal cells from the side effects of chemotherapy. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without dexrazoxane in treating children who have Hodgkin's disease.

Cardiac ToxicityLymphoma

Children's Oncology Group219 participantsStarted Mar 1997

Birmingham, Alabama, United States • Mobile, Alabama, United States • Little Rock, Arkansas, United States +60 more locations

PreviousPage 7 of 8Next

Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms

Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease

Lymphoma Trials in Other Cities

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL

Evaluation of ClearLLab Leukemia and Lymphoma Panels

Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma

Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma

A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma

Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment

Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects

A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma

Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer

Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia

Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)

Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma

Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)

Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma

A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas

A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13

Other Conditions in Florida